Skyrizi for Psoriasis

Skyrizi (risankizumab-rzaa) joins the ever-growing ranks of biologics for the treatment of psoriasis. Skyrizi is new IL-23 inhibitor, which binds to the p19 subunit,  joining Tremfya and Ilumya, and Stelara (which binds to the p40 subunit).  It is approved for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy of phototherapy. Skyrizi has… Read More